Journal for ImmunoTherapy of Cancer (Apr 2024)

Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis

  • Li Zhang,
  • Lawrence Fong,
  • Brittany Davidson,
  • David Y Oh,
  • Frances Fan,
  • Alexander Cheung,
  • Hai Yang,
  • Jun Yan He,
  • Yang-Joon Kim,
  • Elvira Mennillo,
  • Iulia Rusu,
  • Jared Bain,
  • Arjun A Rao,
  • Christopher Andersen,
  • Karen Law,
  • Jessica Tsui,
  • Alan Shen,
  • Divyashree Kushnoor,
  • Yimin Shi,
  • Alexis J Combes,
  • Angela O Pisco,
  • Michael G Kattah

DOI
https://doi.org/10.1136/jitc-2023-008628
Journal volume & issue
Vol. 12, no. 4

Abstract

Read online

Background Colitis caused by checkpoint inhibitors (CPI) is frequent and is treated with empiric steroids, but CPI colitis mechanisms in steroid-experienced or refractory disease are unclear.Methods Using colon biopsies and blood from predominantly steroid-experienced CPI colitis patients, we performed multiplexed single-cell transcriptomics and proteomics to nominate contributing populations.Results CPI colitis biopsies showed enrichment of CD4+resident memory (RM) T cells in addition to CD8+ RM and cytotoxic CD8+ T cells. Matching T cell receptor (TCR) clonotypes suggested that both RMs are progenitors that yield cytotoxic effectors. Activated, CD38+ HLA-DR+ CD4+ RM and cytotoxic CD8+ T cells were enriched in steroid-experienced and a validation data set of steroid-naïve CPI colitis, underscoring their pathogenic potential across steroid exposure. Distinct from ulcerative colitis, CPI colitis exhibited perturbed stromal metabolism (NAD+, tryptophan) impacting epithelial survival and inflammation. Endothelial cells in CPI colitis after anti-TNF and anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) upregulated the integrin α4β7 ligand molecular vascular addressin cell adhesion molecule 1 (MAdCAM-1), which may preferentially respond to vedolizumab (anti-α4β7).Conclusions These findings nominate CD4+ RM and MAdCAM-1+ endothelial cells for targeting in specific subsets of CPI colitis patients.